Page 325 - Read Online

Singh et al. Vessel Plus 2018;2:33 I http://dx.doi.org/10.20517/2574-1209.2018.28 Page 15 of 17

62. Melvin KR, Mason JW. Endomyocardial biopsy: its history, techniques and current indications. CMAJ 1982;126:1381-6.
63. Caves P, Billingham M, Stinson E, Shumway N. Serial transvenous biopsy of the transplanted human heart improved management of
acute rejection episodes. Lancet 1974;303:821-6.
64. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions
1976;6:468-75.
65. Calne RY, White DJG, Rolles K, Smith DP, Herbertson BM. Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A.
Lancet 1978;311:1183-5.
66. Morris T. The matter of the heart. London; 2017.
67. Newton C. Interview: Sir Terence English. Bull Roy Coll Surg Engl 2015;97:289-91.
68. English T. Follow your star. Indiana; 2011.
69. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. NEJM 1984;311:699-705.
70. Patel JK, Kobashigawa JA. Tacrolimus in heart transplant recipients. BioDrugs 2007;21:139-43.
71. European Multicentre Trial G. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial.
Lancet 1983;2:986-9.
72. Starnes VA, Shumway NE. Heart transplantation--Stanford experience. Clin Transpl 1987:7-11.
73. Fung JJ. Tacrolimus and transplantation: a decade in review. Transplantation 2004;77:S41-3.
74. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet
1989;2:1000-4.
75. Jurcevic S, Dunn MJ, Crisp S, Busing K, Rinaldi M, et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial
antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine.
Transplantation 1998;65:1197-202.
76. Behr TM, Richter K, Fischer P, Spes CH, Meiser B, et al. Incidence of humoral rejection in heart transplant recipients treated with
tacrolimus or cyclosporine A. Transplant Proc 1998;30:1920-1.
77. Wang CH, Ko WJ, Chou NK, Wang SS. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with
cyclosporine neoral. Transplant Proc 2004;36:2386-7.
78. Reichart B, Meiser B, Vigano M, Rinaldi M, Martinelli L, et al. European Multicenter Tacrolimus (FK506) heart pilot study: one-year
results--European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998;17:775-81.
79. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, et al. A randomized, multicenter comparison of tacrolimus and
cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J
Heart Lung Transplant 1999;18:336-45.
80. Cooney GF, Jeevanandam V, Choudhury S, Feutren G, Mueller EA, et al. Comparative bioavailability of neoral and sandimmune in
cardiac transplant recipients over 1 year. Transplant Proc 1998;30:1892-4.
81. Eisen HJ, Hobbs RE, Davis SF, Carrier M, Mancini DM, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart
transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine--results at 24
months after transplantation. Transplantation 2001;71:70-8.
82. Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizón Del Prado JM, et al. Superior prevention of acute rejection by tacrolimus vs.
cyclosporine in heart transplant recipients - a large European trial. Am J Transplant 2006;6:1387-97.
83. Kobashigawa JA, Patel J, Furukawa H, Moriguchi JD, Yeatman L, et al. Five-year results of a randomized, single-center study of
tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006;25:434-9.
84. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
85. Eisen HJ, Kobashigawa J, Keogh A, Bourge R, Renlund D, et al. Three-year results of a randomized, double-blind, controlled trial of
mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005;24:517-25.
86. MacKeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis
complex. Neuro-Oncology 2015;17:1550-9.
87. Kobashigawa JA, Pauly DF, Starling RC, Eisen H, Ross H, et al. Cardiac allograft vasculopathy by intravascular ultrasound in heart
transplant patients: substudy from the everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Fail
2013;1:389-99.
88. Andreassen AK, Andersson B, Gustafsson F, Eiskjaer H, Radegran G, et al. Everolimus initiation and early calcineurin inhibitor
withdrawal in heart transplant recipients: a randomized trial. Am J Transplant 2014;14:1828-38.
89. Wlodarczyk Z, Vitko S, Salmela K, Czajkowski Z, Margreiter R. Lipid metabolism in renal transplant patients receiving tacrolimus/
sirolimus combination therapy. Transplant Proc 2005;37:1871-3.
90. Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive
drugs. Circulation 2004;110:3858-65.
91. Tenderich G, Fuchs U, Zittermann A, Muckelbauer R, Berthold HK, et al. Comparison of sirolimus and everolimus in their effects on
blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007;21:536-43.
92. Wahlers T. Cytolytic induction therapy in heart and lung transplantation: the protagonist opinion. Transplant Proc 1998;30:1100-3.
93. Odim J, Wheat J, Laks H, Kobashigawa J, Gjertson D, et al. Peri-operative renal function and outcome after orthotopic heart
transplantation. J Heart Lung Transplant 2006;25:162-6.